254 related articles for article (PubMed ID: 25301770)
1. Synthesis and preliminary investigations into novel 1,2,3-triazole-derived androgen receptor antagonists inspired by bicalutamide.
Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
Bioorg Med Chem Lett; 2014 Nov; 24(21):4948-53. PubMed ID: 25301770
[TBL] [Abstract][Full Text] [Related]
2. Chemical Degradation of Androgen Receptor (AR) Using Bicalutamide Analog-Thalidomide PROTACs.
Kim GY; Song CW; Yang YS; Lee NR; Yoo HS; Son SH; Lee SJ; Park JS; Lee JK; Inn KS; Kim NJ
Molecules; 2021 Apr; 26(9):. PubMed ID: 33926033
[TBL] [Abstract][Full Text] [Related]
3. Preliminary investigations into triazole derived androgen receptor antagonists.
Altimari JM; Niranjan B; Risbridger GP; Schweiker SS; Lohning AE; Henderson LC
Bioorg Med Chem; 2014 May; 22(9):2692-706. PubMed ID: 24726305
[TBL] [Abstract][Full Text] [Related]
4. Circumventing anti-androgen resistance by molecular design.
McGinley PL; Koh JT
J Am Chem Soc; 2007 Apr; 129(13):3822-3. PubMed ID: 17348658
[TBL] [Abstract][Full Text] [Related]
5. Metformin represses androgen-dependent and androgen-independent prostate cancers by targeting androgen receptor.
Wang Y; Liu G; Tong D; Parmar H; Hasenmayer D; Yuan W; Zhang D; Jiang J
Prostate; 2015 Aug; 75(11):1187-96. PubMed ID: 25894097
[TBL] [Abstract][Full Text] [Related]
6. Antagonistic interaction between bicalutamide (Casodex) and radiation in androgen-positive prostate cancer LNCaP cells.
Quéro L; Giocanti N; Hennequin C; Favaudon V
Prostate; 2010 Mar; 70(4):401-11. PubMed ID: 19902473
[TBL] [Abstract][Full Text] [Related]
7. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
[TBL] [Abstract][Full Text] [Related]
8. Interaction mechanism exploration of R-bicalutamide/S-1 with WT/W741L AR using molecular dynamics simulations.
Liu H; An X; Li S; Wang Y; Li J; Liu H
Mol Biosyst; 2015 Dec; 11(12):3347-54. PubMed ID: 26442831
[TBL] [Abstract][Full Text] [Related]
9. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and Biological Evaluation of Bicalutamide Analogues for the Potential Treatment of Prostate Cancer.
Kandil SB; McGuigan C; Westwell AD
Molecules; 2020 Dec; 26(1):. PubMed ID: 33374450
[TBL] [Abstract][Full Text] [Related]
11. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
Gravina GL; Festuccia C; Millimaggi D; Dolo V; Tombolini V; de Vito M; Vicentini C; Bologna M
Prostate; 2008 May; 68(7):793-801. PubMed ID: 18324645
[TBL] [Abstract][Full Text] [Related]
12. Developments in nonsteroidal antiandrogens targeting the androgen receptor.
Liu B; Su L; Geng J; Liu J; Zhao G
ChemMedChem; 2010 Oct; 5(10):1651-61. PubMed ID: 20853390
[No Abstract] [Full Text] [Related]
13. Androgen deprivation and androgen receptor competition by bicalutamide induce autophagy of hormone-resistant prostate cancer cells and confer resistance to apoptosis.
Boutin B; Tajeddine N; Vandersmissen P; Zanou N; Van Schoor M; Mondin L; Courtoy PJ; Tombal B; Gailly P
Prostate; 2013 Jul; 73(10):1090-102. PubMed ID: 23532738
[TBL] [Abstract][Full Text] [Related]
14. Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
Hodgson MC; Astapova I; Hollenberg AN; Balk SP
Cancer Res; 2007 Sep; 67(17):8388-95. PubMed ID: 17804755
[TBL] [Abstract][Full Text] [Related]
15. Effects of steroidal and non-steroidal antiandrogens on wild-type and mutant androgen receptors.
Urushibara M; Ishioka J; Hyochi N; Kihara K; Hara S; Singh P; Isaacs JT; Kageyama Y
Prostate; 2007 Jun; 67(8):799-807. PubMed ID: 17373727
[TBL] [Abstract][Full Text] [Related]
16. Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen.
de Jesus Cortez F; Nguyen P; Truillet C; Tian B; Kuchenbecker KM; Evans MJ; Webb P; Jacobson MP; Fletterick RJ; England PM
ACS Chem Biol; 2017 Dec; 12(12):2934-2939. PubMed ID: 28981251
[TBL] [Abstract][Full Text] [Related]
17. Discovery of deshydroxy bicalutamide derivatives as androgen receptor antagonists.
Kandil S; Lee KY; Davies L; Rizzo SA; Dart DA; Westwell AD
Eur J Med Chem; 2019 Apr; 167():49-60. PubMed ID: 30743097
[TBL] [Abstract][Full Text] [Related]
18. Learning from estrogen receptor antagonism: structure-based identification of novel antiandrogens effective against multiple clinically relevant androgen receptor mutants.
Liu B; Geng G; Lin R; Ren C; Wu JH
Chem Biol Drug Des; 2012 Mar; 79(3):300-12. PubMed ID: 22151347
[TBL] [Abstract][Full Text] [Related]
19. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
Söderholm AA; Viiliäinen J; Lehtovuori PT; Eskelinen H; Roell D; Baniahmad A; Nyrönen TH
J Chem Inf Model; 2008 Sep; 48(9):1882-90. PubMed ID: 18712859
[TBL] [Abstract][Full Text] [Related]
20. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome.
Hara T; Miyazaki J; Araki H; Yamaoka M; Kanzaki N; Kusaka M; Miyamoto M
Cancer Res; 2003 Jan; 63(1):149-53. PubMed ID: 12517791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
